Acute Respiratory Distress Syndrome Pipeline Review H2 2020
Dublin, Aug. 28, 2020 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
The latest Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Acute Respiratory Distress Syndrome pipeline landscape.
The pipeline guide provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 28, 22, 4, 50, 16 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Scope of the report:
The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews the latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)
Key report benefits:
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Acute Respiratory Distress Syndrome - Overview
Acute Respiratory Distress Syndrome - Therapeutics Development
Acute Respiratory Distress Syndrome - Therapeutics Assessment
Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
Acute Respiratory Distress Syndrome - Drug Profiles
Acute Respiratory Distress Syndrome - Dormant Projects
Acute Respiratory Distress Syndrome - Discontinued Products
Acute Respiratory Distress Syndrome - Product Development Milestones
Companies Mentioned
A6 Pharmaceuticals LLC
AbbVie Inc
Abivax SA
Aerogen Ltd
Aerpio Pharmaceuticals Inc
Akebia Therapeutics Inc
Alexion Pharmaceuticals Inc
Algernon Pharmaceuticals Inc
Ampio Pharmaceuticals Inc
APEIRON Biologics AG
Bayer AG
Baylx Inc
BeiGene Ltd
BioCardia Inc
Biocon Ltd
BioMarck Pharmaceuticals Ltd
Biophytis SA
Biotest AG
Biovista Inc
Bioxytran Inc
Bonac Corp
Bonus BioGroup Ltd
CohBar Inc
Commence Bio Inc
Curacle Co Ltd
Cynata Therapeutics Ltd
Cytopeutics Pte Ltd
Diffusion Pharmaceuticals Inc
Dimerix Ltd
Edesa Biotech Inc
Educell doo
Emergent BioSolutions Inc
Emtora Biosciences
Eunoia Biotech LLC
Evgen Pharma Plc
Exvastat Ltd
Faron Pharmaceuticals Oy
FibroGenesis LLC
Foresee Pharmaceuticals Co Ltd
Grifols SA
Hemarina SA
Histocell SL
Human Life CORD Japan Inc
Hydra Biosciences Inc
Iltoo Pharma
Immune Regulation Ltd
In2cure AB
Insmed Inc
IsletOne AB
LTT Bio-Pharma Co Ltd
MannKind Corp
Matrix Biomed Inc
Meridigen Biotech Co Ltd
Mesoblast Ltd
Neutrolis Inc
Northern Therapeutics Inc
Novellus Inc
Noxopharm Ltd
NS Pharma Inc
Orbsen Therapeutics Ltd
Oryzon Genomics SA
PharmAbcine Inc
Pharming Group NV
PhaseBio Pharmaceuticals Inc
Pluristem Therapeutics Inc
Predictive Biotech Inc
R Pharm
Relief Therapeutics Holding AG
Restore Therapeutics LLC
Reven Pharmaceuticals Inc
Roivant Sciences Ltd
SFA Therapeutics LLC
SolAeroMed Inc
SynAct Pharma AB
Syndax Pharmaceuticals Inc
Thetis Pharmaceuticals LLC
Trevena Inc
Vasomune Inc
Veru Inc
Xfibra Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/29wu9v
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900